<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961038</url>
  </required_header>
  <id_info>
    <org_study_id>13014</org_study_id>
    <secondary_id>2008-006771-79</secondary_id>
    <nct_id>NCT00961038</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Randomized, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLD II - III), Following Inhalation of Ciprofloxacin PulmoSphereÂ® Inhalation Powder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of the study are to investigate the safety, tolerability and levels of
      ciprofloxacin in the lung after single and multiple inhalative administration to patients
      with moderate to severe COPD (stage II-III according to GOLD Criteria)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Within 28 days after first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>Within 28 days after first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary function test</measure>
    <time_frame>Within 28 days after first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse-oximetry</measure>
    <time_frame>Within 12 days after first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ciprofloxacin concentrations in blood</measure>
    <time_frame>Within 14 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciprofloxacin concentrations in urine</measure>
    <time_frame>Within 14 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciprofloxacin concentrations in sputum</measure>
    <time_frame>Within 14 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciprofloxacin concentrations in mouth fluid</measure>
    <time_frame>Within 7 days after first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin (PulmoSphere, BAYQ3939)</intervention_name>
    <description>32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin (PulmoSphere, BAYQ3939)</intervention_name>
    <description>48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with COPD, 40 to 75 years of age

          -  Diagnosis of COPD

          -  Airway obstruction with a post-bronchodilator Forced Expiratory Volume (FEV1) of
             &gt;/=30% and &lt;/=65% of predicted and a post-bronchodilator FEV1 / Forced Vital Capacity
             (FVC) of &lt;/=70%

          -  Current or ex-smokers with a smoking history of more than 10 pack-years

          -  Patients must be able to produce acceptable induced sputum samples (as defined in the
             Study Procedure Manual)

          -  Normal body weight: Body Mass Index (BMI) between 19 and 35 kg/m2

        Exclusion Criteria:

          -  Significant respiratory disease other than COPD as bronchial asthma, Cystic fibrosis
             or clinically evident bronchiectasis

          -  More than one COPD exacerbation within 12 months and within 8 weeks prior to screening

          -  total blood eosinophil count &gt;/=600/mm3

          -  Thoracotomy with pulmonary resection

          -  Regularly use of daytime oxygen therapy for more than one hour per day and in the
             investigator's opinion will be unable to abstain from the use of oxygen therapy during
             clinic visits

          -  Hypersensitivity to the investigational drug or to other quinolones and/or to inactive
             constituents of the inhalation powder

          -  Hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline
             solution

          -  Patients with a history of severe allergies, non-allergic drug reactions, or multiple
             drug allergies

          -  Concomitant use of medication which could interfere with the investigational drug.
             Before study drug administration a wash out period of more than 5 half lives has to be
             considered

          -  Concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy
             with

               -  fluoroquinolones

               -  Oral beta-andrenergics, beta blockers

               -  oral steroids

               -  Methylxanthines: 24-hour washout of short-acting theophylline and 48-hour washout
                  of long-acting theophylline prior to pre-study examination

               -  Antihistamines, antileukotrienes prescribed for asthma

               -  oral cromolyn sodium or oral nedocromil sodium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciprofloxacin</keyword>
  <keyword>Inhalation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

